自引率: 0.6%
被引量: 2307
通过率: 暂无数据
审稿周期: 暂无数据
版面费用: 暂无数据
国人发稿量: 暂无数据
投稿须知/期刊简介:
Each issue of Rheumatic Disease Clinics reviews new diagnostic and management techniques for a single clinical problem--and makes them simple to apply. Its concise, comprehensive, and its editors and authors are respected experts.
期刊描述简介:
Each issue of Rheumatic Disease Clinics reviews new diagnostic and management techniques for a single clinical problem--and makes them simple to apply. Its concise, comprehensive, and its editors and authors are respected experts.
-
Imaging in Juvenile Idiopathic Arthritis.
Juvenile idiopathic arthritis (JIA) poses clinical challenges because of its heterogeneous categories of chronic arthritis. Although conventional radiography aids with assessment of joint damage, MRI and ultrasound offer more sensitive evaluation of joint changes related to inflammation and damage in JIA. MRI and ultrasound have the potential to complement clinical assessment, monitor inflammation and damage, guide treatment decisions, and improve outcomes in JIA. Future research aims to enhance standardization and reliability and bolster the predictive value of imaging in clinical practice.
被引量：- 发表：1970
-
Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease.
Interstitial lung disease (ILD) complicates connective tissue disease (CTD) with variable incidence and is a leading cause of death in these patients. To improve CTD-ILD outcomes, early recognition and management of ILD is critical. Blood-based and radiologic biomarkers that assist in the diagnosis CTD-ILD have long been studied. Recent studies, including -omic investigations, have also begun to identify biomarkers that may help prognosticate such patients. This review provides an overview of clinically relevant biomarkers in patients with CTD-ILD, highlighting recent advances to assist in the diagnosis and prognostication of CTD-ILD.
被引量：- 发表：2024
-
Connective Tissue Disease Associated Interstitial Lung Disease.
Connective tissue disease associated interstitial lung disease (CTD-ILD) is a heterogenous collection of conditions with a diverse spectrum of interstitial lung disease (ILD) manifestations. Currently, clinical practice of lung-directed immunosuppression in CTD-ILD is supported by several randomized, placebo-controlled trials (RCTs) in patients with scleroderma and several observational, retrospective studies in other autoimmune conditions. However, given the harm of immunosuppression in idiopathic pulmonary fibrosis, there is an urgent need for RCTs of immunosuppression and antifibrotic agents in fibrotic CTD-ILD populations as well as the study of intervention in patients with subclinical CTD-ILD.
被引量：- 发表：2024
-
Interstitial Lung Disease: How Should Therapeutics Be Implemented?
Systemic sclerosis-interstitial lung disease (SSc-ILD) is a major complication of SSc resulting in important morbidity and mortality. Next to cyclophosphamide and mycophenolate mofetil, tocilizumab and nintedanib have proven efficacy in the treatment of SSc-ILD. The highly variable course of SSc-ILD, the complexity in determining and predicting the progression of SSc-ILD, and the diversity of treatment options for SSc-ILD, pose many challenges for everyday clinical practice. In this review, currently available evidence for monitoring and treatment of SSc-ILD is summarized and areas where additional evidence is highly desirable are discussed.
被引量：3 发表：2023
-
Outcome Measures in Pediatric Rheumatic Disease.
Reliable and responsive outcome measures that accurately detect changes in disease state, activity, and damage are crucial to conducting observational and interventional trials that can directly transform care for children with rheumatic disease. A combination of consensus-based and direct measurement approaches has led to the development of several validated, composite outcome measures in juvenile idiopathic arthritis, juvenile dermatomyositis, childhood-onset systemic lupus erythematosus, and pediatric vasculitis. This review outlines clinician-reported, disease-specific outcome measures developed for these conditions.
被引量：- 发表：2021
